ANSTO's research capabilities, led by the OPAL nuclear research reactor and associated instruments provide access to users investigating areas as diverse as materials, life sciences, climate change and mining/engineering.
Dr Lidia Matesic
Position: Radiochemist
Phone: +61 (0)2 9717 7337
Email: lidia.matesic@ansto.gov.au
Role at ANSTO
Lidia is involved in radiochemistry development research, working primarily with 18F to develop new 18F labelled radiotracers.
Background
Lidia completed a PhD in organic and medicinal chemistry at the University of Wollongong in 2011. Following her degree, she joined ANSTO LifeSciences as a Post-Doctoral Research Fellow before accepting her position as a Radiochemist later in the year.
Research interests and areas of expertise
Lidia’s research interests include 18F radiolabelling using conventional, automated and microfluidic techniques and the development of novel 18F prosthetic groups for incorporation into new radiotracers. Lidia has expertise in 18F radiochemistry, microfluidics, ex vivo radiometabolism studies, organic synthesis and medicinal chemistry.
Qualifications & Achievements
PhD (Chemistry), University of Wollongong (2011)
Bachelor of Medicinal Chemistry (Honours), University of Wollongong (2006)
Member of the Royal Australian Chemical Institute (MRACI CChem) and Women in Nuclear
Associate Editor for the journal, Anti-Cancer Agents in Medicinal Chemistry
France-Australia Science Innovation Collaboration Early Career Fellowship (2012)
Royal Society of NSW Scholarship (2010)
AusBiotech-GSK Student Excellence Award – NSW (2009)
Johnson & Johnson Honours Research Prize in Medicinal Chemistry (2007)
Australian Federation of University Women – NSW Inc. Jamieson Award (2007)
Key Publications
Krause-Heuer, A. M., Howell, N. R., Matesic, L., Dhand, G., Young, E. L., Burgess, L., Jiang, C. D., Lengkeek, N. A., Fookes, C. J. R., Pham, T. Q., Sobrio, F., Greguric, I., Fraser, B. H. A new class of fluorinated 5-pyrrolidinylsulfonyl isatin caspase inhibitors for PET imaging of apoptosis. MedChemComm, advance article (2013) DOI: 10.1039/C2MD20249B
Matesic, L., Locke, J. M., Vine, K. L., Ranson, M., Bremner, J. B., Skropeta, D. Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2-diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives. Tetrahedron, 68(34), 6810-6819. (2012) DOI: 10.1016/j.tet.2012.06.049
Indira Chandran, V., Matesic, L., Locke, J. M., Skropeta, D., Ranson, M., Vine, K. L. Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Letters, 316(2), 151-156. (2012) DOI: 10.1016/j.canlet.2011.10.021
Vine, K. L., Indira Chandran, V., Locke, J. M., Matesic, L., Lee, J., Skropeta, D., Bremner, J. B., Ranson, M. Targeting urokinase and the transferrin receptor with novel, anti-mitotic N alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth. Current Cancer Drug Targets, 12(1), 64-73. (2012)
Matesic, L., Locke, J. M., Vine, K. L., Ranson, M., Bremner, J. B., Skropeta, D. Synthesis and hydrolytic evaluation of acid-labile imine-linked cytotoxic isatin model systems. Bioorganic & Medicinal Chemistry, 19(5), 1771-1778. (2011) DOI: 10.1016/j.bmc.2011.01.015
Vine, K. L., Matesic, L., Locke, J. M., Ranson, M., Skropeta, D. Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000 2008. Anti-Cancer Agents in Medicinal Chemistry, 9(4), 397-414. (2009)
Matesic, L., Locke, J. M., Bremner, J. B., Pyne, S. G., Skropeta, D., Ranson, M., Vine, K. L. N-Phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorganic & Medicinal Chemistry, 16(6), 3118-3124. (2008) DOI: 10.1016/j.bmc.2007.12.026